Stability of Dry Powder Inhaler Protein Formulations

Join this webcast to learn formulation strategies to eliminate cold chain requirements for proteins using dry powders manufactured by spray drying.

Register Free: https://www.pharmtech.com/pt/inhaler-protein

Event Overview:

Inhaled delivery of biotherapeutic active pharmaceutical ingredients (APIs) is of growing importance in the pharmaceutical pipeline. When formulated as dry powders, local delivery of biologic molecules is possible without the need for cold-chain storage, facilitating a patient-centric treatment approach. In this webinar, the use of spray drying to manufacture dry powder formulations of protein APIs will be discussed. A case study will also be presented, in which an inhaled formulation of the antibody bevacizumab demonstrated 24-month stability at 25°C.

Key Learning Objectives

• Understand formulation approaches for dry powder inhalers (DPIs) with protein-based APIs
• Describe the key attributes of a room-temperature stable spray-dried powder of a biotherapeutic API
• Appreciate the patient centricity of DPI formulations for lung delivery

Who Should Attend

• Formulation and development scientists
• Principal investigators
• Biotech executives
• Pharma startup CSOs

Speaker:

Kim Shepard
Associate Director, Principal Engineer, R&D
Lonza Small Molecules

Kim Shepard is a Principal Engineer in the research group at Lonza's site in Bend, Oregon, USA, where she has worked since 2015. She leads projects focused on developing new process and formulation technologies for inhaled delivery and bioavailability enhancement. Kim’s areas of expertise include the formulation and manufacturing of spray-dried dispersions for inhalation and oral delivery, as well as the physics of polymers and amorphous materials. Kim received her bachelor’s degree and master’s degree in Chemical Engineering from Stevens Institute of Technology and her Ph.D. in Chemical Engineering from Princeton University.

Register Free: https://www.pharmtech.com/pt/inhaler-protein